Peptide therapy on TikTok: separating hype from human data

What did @justagrownwoman actually say?

She described a three-step protocol to "get the most" out of MOTS-c, a mitochondria-derived peptide. Her logic: MOTS-c made her tired before because her mitochondria were already damaged. Her fix is to first use PQQ because it "literally creates mitochondria," then run SS-31 for a couple of weeks to repair existing damaged mitochondria, and only then introduce MOTS-c. She's promoting affiliate links for at least two of the three products mentioned.

She repeatedly flagged this as not medical advice and acknowledged others with healthier mitochondrial function might not need the full stack. That disclaimer does not eliminate the influence this kind of content has on people self-experimenting with research compounds, but it matters.

Does the science back this up?

The underlying concept, that mitochondrial health affects how you respond to mitochondria-targeting peptides, is biologically plausible. The specific claims about PQQ and SS-31 are more complicated.

PQQ does have evidence for supporting mitochondrial biogenesis. A 2010 study by Rucker et al. in the Journal of Nutrition showed PQQ deprivation impaired mitochondrial function in mice, and supplementation promoted biogenesis via PGC-1alpha pathways. Human data is thinner. A 2016 randomized trial by Harris et al. in Functional Foods in Health and Disease found modest improvements in energy metabolism markers in healthy adults, but sample sizes were small and effect sizes were not dramatic. Saying PQQ "literally creates mitochondria" oversimplifies a real but modest signaling effect.

SS-31, also known as elamipretide, is a more serious compound. It targets cardiolipin in the inner mitochondrial membrane and has shown genuine mitochondrial protective effects in preclinical models. A 2020 study by Chatfield et al. in JCI Insight demonstrated improved mitochondrial function in patients with Barth syndrome. The catch: this was an IV-administered pharmaceutical in a rare disease population. The injectable peptide version circulating in research chemical markets is not the same thing, and extrapolating that data to healthy aging is a real stretch.

MOTS-c itself has legitimate preclinical backing. Lee et al. published in Cell Metabolism in 2015 showing MOTS-c regulates metabolic homeostasis and improves insulin sensitivity in mice. Human trials remain limited and early-stage.

What did they get wrong (or right)?

She got the broad concept right. Mitochondrial dysfunction is a real factor in fatigue and cellular energy production. The idea that you might get a paradoxical fatigue response from an energy-related peptide if your underlying cellular machinery is compromised is not absurd. Some researchers studying MOTS-c have noted that metabolic context matters for its effects.

Where she overreaches: PQQ does not "literally create" mitochondria in any simple sense. It upregulates signaling pathways that can promote biogenesis over time. That is a meaningful difference. You are not installing new batteries. You are nudging a signaling network that may, under the right conditions, support the growth of new mitochondria over weeks.

The SS-31 claim is the shakiest part. Describing it as something that "repairs broken mitochondria" before you run MOTS-c treats a research compound with a narrow evidence base as if it's a proven prep protocol. The two-week timeline she proposes has no clinical backing for sequencing with MOTS-c specifically.

She also has affiliate links for these products. That financial relationship should be weighed when evaluating her enthusiasm for this particular stack.

What should you actually know?

MOTS-c, SS-31, and research-grade PQQ supplements exist in very different regulatory and evidence categories. MOTS-c and SS-31 are not FDA-approved for any indication. They are sold as research compounds. Elamipretide, the pharmaceutical version of SS-31, is in clinical development but has not cleared approval. Sourcing, purity, and dosing of these compounds from commercial peptide vendors is entirely unverified.

The fatigue response she described from her first MOTS-c experience has no confirmed mechanistic explanation. It may reflect dosing, timing, product quality, or individual variation. Attributing it specifically to mitochondrial damage and designing a multi-compound prep protocol around that theory is speculative, even if it sounds reasonable on its face.

Anyone considering these compounds should consult a physician familiar with peptide therapy, not a TikTok protocol, regardless of how thoughtfully it is presented. The biology here is genuinely interesting. The self-experimentation and affiliate-linked product recommendations are a different matter entirely.